-continued

<400> SEQUENCE: 102

nnaaccgtat cggcgatatc ggttnnnnng 30

<210> SEQ ID NO 103
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CpG
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(2)
<223> OTHER INFORMATION: n is a G-phosphorothioate
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (25)..(29)
<223> OTHER INFORMATION: n is a G-phosphorothioate

<400> SEQUENCE: 103

nnaaccgtat gcggcatatc ggttnnnnng 30

<210> SEQ ID NO 104
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 104

Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro
1 5 10

1-8. (canceled)

9. An allogeneic tumor cell vaccine comprising:

(1) a tumor cell line variant comprising

(a) two or more stably expressed recombinant membrane bound immunomodulator molecules selected from IgG1, CD40L, TNF-alpha, and Flt-3L peptides; and

(b) stably expressed recombinant soluble GM-CSF peptides and

(2) a pharmaceutically acceptable carrier;

wherein an immune stimulatory amount of the tumor cell line variant is effective to elicit an immune response that improves progression free survival, overall survival, or both relative to placebo controls.

10. The allogeneic tumor cell vaccine of claim **9**, wherein the tumor cell line variant expresses two or more of:

(a) a membrane bound IgG1 immunomodulator comprising an amino acid sequence that has at least 60% identity to SEQ ID NO: 45;

(b) a membrane bound CD40L immunomodulator comprising an amino acid sequence that has at least 60% identity to SEQ ID NO: 7;

(c) a membrane bound form of TNF-alpha immunomodulator comprising an amino acid sequence that has at least 60% identity to SEQ ID NO: 11;

(d) a membrane bound form of Flt-3L immunomodulator comprising an amino acid sequence that has at least 60% identity to SEQ ID NO: 14; and

(e) a soluble GM-CSF immunomodulator comprising an amino acid sequence that has at least 60% identity to SEQ ID NO: 13.

11. The allogeneic tumor cell vaccine of claim **9**, wherein the tumor cell line variant comprises a membrane bound chimeric fusion protein comprising a fusion of the CD40L immunomodulator and the TNF-alpha immunomodulator.

12. The allogeneic tumor cell vaccine of claim **11**, wherein the CD40L immunomodulator comprises an amino acid sequence that has at least 60% identity to SEQ ID NO: 9, and the TNF-alpha immunomodulator comprises an amino acid sequence that has of at least 60% identity to SEQ ID NO: 10.

13. The allogeneic tumor cell vaccine of claim **9**, wherein the tumor cell line variant comprises a membrane bound TNF-alpha immunomodulator with an amino acid sequence comprising at least 60% identity to SEQ ID NO: 11.

14. (canceled)

15-19. (canceled)

* * * * *